Redeye will consider raising its near-term estimates on the back of this Q3 report, which crushed ou...
Orderingången i Q3 var stark och efterfrågan är fortsatt god.
Cibus posted Q3 net operating income of EUR 26.2m, up 36% y/y on the back of acquisitions and 1% abo...
Redeye comments on GiG’s Q3-results which came in slightly below our estimates while the start to Q4...
Redeye comments on G5’s Q3-results where revenue and EBITDA was in line with expectations while EBIT...
Redeye updates on Invisio after the company's Q3-results which showed solid growth and improved prof...
Aptahem har publicerat sin delårsrapport för tredje kvartalet 2022.
Redeye ser positivt på att BioArctic fortsätter bredda sin pipeline – nu med en behandling av den sä...
Analysguiden initierar bevakning av det snabbväxande SaaS-bolaget SmartCraft, vilka levererar sin lö...
Redeye comments on Spago’s Q3 2022 report, and we estimate that the company is closing in on wrappin...
Redeye comments on Respiratorius following the release of its shortened fiscal year 2022 Q2 report.
Tydlig tillväxtprofil Devyser är ett snabbväxande diagnostikbolag med ambitionen att bli en ledande ...
Redeye’s comments on the Q3 report that was published earlier this morning.
Det investeras kraftigt i järnvägstransport och avyttringen av Riksterminalen i Sigtuna börjar visa ...
Redeye sees a solid Q3 report from Hanza with an EBITA in line with our expectations.
NoHo Partners reported Q3 EBIT of EUR 8.4m, +10% versus Refinitiv consensus and +6% versus Nordea.
Sammantaget visade rapporten på nytt att Amhult 2 har hanterat förutsättningarna på ett väl sätt.
FY’22 guidance revised to 3.0-3.4kboe/d Workover program finalised at the Tie field New major shareh...
Relais will for the first time report in accordance with IFRS standards in its Q3 results on 10 Nove...
Redeye retains its positive view on Transtema following a solid Q3 report, showing high organic and ...
